推荐产品
生化／生理作用
LJH685 is potent pan-RSK inhibitor that targets RSK N-terminal kinase domain (NTKD) ATP-binding site (IC50/[ATP] = 6 nM/5 μM/RSK1, 5 nM/20 μM/RSK2, 4 nM/10 μM/RSK3). LJI308 effectivelfy inhibits MAPK pathway-dependent cancer growth (EC50 values of 0.73 μM/MDA-MB-231 and 0.79 μM/H358) by reducing the phosphorylation level of cellular Y-box binding protein-1 (YB1) Ser102 (EC50 = 0.2-0.3 μM; MDA-MB-231 and H358), but not that of ribosomal S6 protein (S6RP) S235/236.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Xiaolin Guan et al.
Cell death discovery, 8(1), 84-84 (2022-02-27)
Breast cancer is one of the leading causes of mortality among women. Triple-negative breast cancer (TNBC) is responsible for a large percentage of all breast cancer deaths in women. This study demonstrated the function of Myb-like, SWIRM, and MPN domains
Dewei Jiang et al.
Cell death and differentiation, 29(6), 1283-1295 (2022-01-14)
Y-box binding protein 1 (YB-1) is a well-known oncogene highly expressed in various cancers, including basal-like breast cancer (BLBC). Beyond its role as a transcription factor, YB-1 is newly defined as an epigenetic regulator involving RNA 5-methylcytosine. However, its specific
Ida Aronchik et al.
Molecular cancer research : MCR, 12(5), 803-812 (2014-02-21)
The p90 ribosomal S6 kinase (RSK) family of serine/threonine kinases is expressed in a variety of cancers and its substrate phosphorylation has been implicated in direct regulation of cell survival, proliferation, and cell polarity. This study characterizes and presents the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门